Loyal: Funding, Investors & Team (Oct 2026)
Loyal is a biotechnology company dedicated to increasing the lifespan of dogs by creating medications that have the potential to slow down the aging process. Their goal is to prevent or delay age-related diseases such as cancer and dementia by controlling the aging processes through the development of drugs. By regulating these processes, Loyal aims to reduce the severity and occurrence of age-related illnesses, ultimately leading to a longer period of good health for dogs and humans alike.
Loyal has raised $72.4M across 3 funding rounds on record, the most recent a Series B of $22.0M announced in Feb 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Loyal Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Loyal Funding Rounds
Loyal raised $5.4M in an undisclosed round announced in Jun 2021.
2.8 years later, an undisclosed round of $45.0M was announced in Mar 2024.
11 months later, a Series B of $22.0M was announced in Feb 2025.
Loyal Founders and Leadership Team
No contact details are on record for this team yet.
Loyal Funding Compared to Other Biotechnology Startups
Loyal's latest round of $22.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Loyal in Biotechnology and San Francisco
Companies Similar to Loyal
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Loyal Funding FAQs
What does Loyal do?
Loyal is a biotechnology company dedicated to increasing the lifespan of dogs by creating medications that have the potential to slow down the aging process. Their goal is to prevent or delay age-related diseases such as cancer and dementia by controlling the aging processes through the development of drugs. By regulating these processes, Loyal aims to reduce the severity and occurrence of age-related illnesses, ultimately leading to a longer period of good health for dogs and humans alike.
How much funding has Loyal raised?
Loyal has raised $72.4M across 3 rounds on record. The most recent is a Series B of $22.0M announced in Feb 2025.
When did Loyal last raise funding?
Loyal's most recent funding round on record is a Series B of $22.0M, announced in Feb 2025.
Who founded Loyal?
FundedIQ lists Jevon Christian (Founder), Venelina Vasileva (Founder) at Loyal.
Who is the CEO of Loyal?
Celine Halioua is listed as CEO at Loyal.
Where is Loyal headquartered?
Loyal is based in San Francisco, California, United States.
How many employees does Loyal have?
Loyal is in the 101-250 employee band.
How does Loyal's funding compare to other Biotechnology startups?
Loyal's latest round of $22.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Loyal Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Loyal is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.